1.1800 0.00 (0.00%)
After hours: 4:48PM EST
|Bid||1.1900 x 3100|
|Ask||1.2100 x 1400|
|Day's Range||1.1759 - 1.2500|
|52 Week Range||0.7400 - 11.5000|
|Beta (5Y Monthly)||2.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 16, 2020 - Feb 20, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
TEL AVIV, Israel, Jan. 27, 2020 -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced strong preliminary unaudited revenue for the fourth quarter and reported an inducement grant to the company’s new Chief Executive Officer, Marvin Slosman, who assumed the role effective January 1, 2020. InspireMD anticipates that preliminary unaudited revenue for the fourth quarter ended December 31, 2019, will be within a range of $1,000,000 to $1,025,000, representing estimated growth of 22%-25% over the comparable period in 2018.
Zacks.com featured highlights include: Civeo, InspireMD, Westport Fuel Systems, Genesco and Radware
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced that James Barry, Ph.D. is stepping down as President and Chief Executive Officer to pursue other opportunities. The company’s Board of Directors has appointed life sciences industry veteran Marvin Slosman as new Chief Executive Officer, effective January 1, 2020.
Medical device company Inspire MD (NSPR), best known for developing innovative MicroNet technology for vascular procedures, has attracted investor attention today following its release of updated registry data at the 2019 VEITH Symposium. As of this writing, Inspire MD shares are soaring nearly 15%.According to the findings, NSPR’s CGuard Embolic Prevention System (EPS) for the prevention of strokes caused by carotid artery disease saw procedural success in 100% of patients in the IRONGUARD 2 study. Not to mention the system isn’t associated with any major periprocedural, 30-day or one-year neurological complications.“The data from long term investigator-initiated multi-center studies presented at VEITH continue to suggest that treatment of carotid artery stenosis with CGuard™ EPS results in lower rates of stroke and restenosis than other treatments presented, including first generation carotid stents, novel double carotid layer stents, and surgical or hybrid techniques,” CEO James Barry, Ph.D. stated.To this end, investors have been left wondering if this positive development represents a turning point for NSPR, which has seen shares tumble year-to-date.H.C. Wainwright analyst Vernon Bernardino believes that this is in fact the case, arguing that the company has already taken several steps in the right direction. The analyst has recently reiterated a Buy rating on NSPR stock along with a $5 price target, as he believes shares could skyrocket 372% over the next twelve months. (To watch Bernardino's track record, click here)Solid Quarterly Performance In its third quarter, NSPR reported that revenue had increased 22% year-over-year to reach $939,000. That was just to kick things off. CGuard EPS saw a record number of orders during the quarter, resulting in sales growth of 41% year-over-year.Bernardino points out that this result was noteworthy as it occurred during a “seasonally soft quarter”, suggesting that awareness of the clinical advantages of CGuard in terms of both conventional carotid stent implantation and carotid endarterectomy (CAE) is increasing. “We believe InspireMD’s strong CGuard sales growth is under-appreciated…InspireMD shares are an attractive value proposition ahead of our projection for continued CGuard sales growth,” he explained.Strong Traction in Education and Outreach ProgramsThe analyst highlights NSPR’s commercial activities like its Centers of Excellence training program as having a positive impact on the awareness of CGuard EPS’s strong clinical data and safety among physicians. Back in 2018, the program was created to train interventional cardiologists using hands-on live patient cases. This program as well as others have contributed to the product’s international expansion.“We believe target introductions in key territories, namely Brazil, which is the fifth-largest market in the world for interventional cardiology procedures, as well as South Korea, Taiwan, Japan and China, which all have attractive pricing for carotid devices, coupled with maturity in the company’s distribution network, represent opportunities for future strong CGuard sales growth,” Bernardino commented.Increased Awareness Through Presentations and Publications Recent presentations and publications have also gone a long way in terms of raising awareness. At the joint Congress of the World Heart Federation and the European Society of Cardiology, the company presented data on a patient level mesh stent meta-analysis from four trials for the first time. The H.C. Wainwright analyst notes that in just one session, NSPR was able to demonstrate the superiority of CGuard EPS versus both first-generation carotid stents and second-generation double layer or mesh-covered carotid devices.The Bottom LineAs Bernardino is the only analyst that has rated the stock in the last three months, NSPR is difficult to gauge. With 1 Buy compared to no Holds or Sells, the consensus is a ‘Moderate Buy.'To find good ideas for biotech stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today reported on updated registry study data presented at the 2019 VEITH Symposium, which was held November 19-23 in New York City.
Strong revenue driven by record orders of CGuard™ EPS Management to host investor conference call today, November 12, at 8:30am ET TEL AVIV, Israel, Nov. 12, 2019 --.
TEL AVIV, Israel, Nov. 05, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the.
InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced the pricing of an underwritten public offering of 2,777,777 units at a price to the public of $1.80 per unit. InspireMD expects to receive aggregate gross proceeds of approximately $5 million from the offering, assuming no exercise of the underwriter’s option to purchase additional securities. Each unit contains one share of common stock (or common stock equivalent) and one Series E warrant to purchase one share of common stock at an exercise price of $1.80 per share.
TEL AVIV, Israel, Sept. 09, 2019 -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by.
TEL AVIV, Israel, Sept. 09, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by.
With the latest escalation of the U.S.-China trade war on August 23, investors are looking for defensible stocks that still represent compelling investments in a volatile market. According to research from Goldman Sachs, these investments can be found within the healthcare sector. “Funds have steadily reduced the share of market cap owned among the stocks most exposed to US-China trade conflict, such as semiconductors,” Goldman strategist Ben Snider wrote in a note to clients. He added that even with the risk of health care regulation that attracted attention from investors earlier in the year, healthcare stocks still present a strong opportunity given the economic landscape. We looked at 4 of the top August 23 gainers in this sector to find the most compelling investments. Let’s dive in. Endologix, Inc. (ELGX)Endologix develops innovative and minimally invasive technologies for aortic disorders including abdominal aortic aneurysms (AAA). With shares gaining 4% on August 23, some analysts argue this healthcare stock is just getting started. The jump comes one day after ELGX canceled its agreement with Piper Jaffray for the at-the-market sale of up to $25 million of its common stock. While this would have given the company additional capital, several recent positive developments suggest ELGX is still on track for long-term growth.On August 8, the company announced its agreement to give Boston Scientific (BSX) exclusive rights to distribute its Endologix products in China. Not to mention that same day it received Investigational Device Exemption (IDE) approval from the FDA to begin a new pivotal study evaluating the safety and effectiveness of the Nellix Chimney EndoVascular Aneurysm Sealing System (ChEVAS) for endovascular treatment of complex AAA.Based on all of the above factors, BTIG analyst Sean Lavin reiterated his Buy rating and $12 price target on August 12. The 3.5-star analyst believes share prices could soar 118% over the next twelve months.All in all, the Street is cautiously optimistic on this healthcare stock. ELGX has a ‘Moderate Buy’ analyst consensus and an $8 average price target, suggesting 51% upside. T2 Biosystems Inc. (TTOO) This healthcare stock develops and commercializes medical diagnostic products for the detection of additional species and antibiotic resistance markers of sepsis pathogens as well as tests for Lyme disease. In the last five days, shares are up 49% with shares gaining over 3% on August 23 alone.Shares got a boost shortly after T2 announced that it had entered into an exclusive agreement that will allow the company to introduce its rapid diagnostic technologies, including the T2Bacteria and T2Candida Panels, and enter into new markets in Australia, Fiji and New Zealand. These countries have approximately 1,150 hospitals that could benefit from T2’s products. It doesn’t hurt that its T2Bacteria Panel received approval for a New Technology Add-on Payment (NTAP) from the Centers for Medicare & Medicaid Services (CMS) on August 6, making it the first and only in-vitro diagnostic test to ever receive approval for NTAP.“We view this development as an unexpected victory that sort of came out of left field (as management had not indicated plans to pursue this add- on payment). While management has indicated that pricing (cost) of their panels has historically not been a meaningful barrier to driving adoption, we think that anything sold into a hospital is scrutinized from a cost and ROI perspective, even if it is clear that the technology has clinical utility for the patient,” noted Canaccord Genuity analyst Mark Massaro. As a result, the five-star analyst reiterated his Buy rating and $2.50 price target on August 6. He believes shares could soar 110% over the next twelve months. Wall Street takes a less bullish stance on TTOO. It has a ‘Hold’ analyst consensus and a $1 average price target, indicating 22% upside potential. InspireMD Inc. (NSPR)The vascular procedure technology company saw shares jump almost 2% on August 23 as well as a 32% gain in the last five days, with some analysts saying there’s no sign of a slowdown on the horizon.The upward move follows the announcement of its planned public offering of units, each consisting of one common share and one Series E warrant. Investors have expressed concern regarding a letter from the NYSE American it received on August 7, 2019. It indicated that InspireMD does not meet a certain listing standards due to the fact that the company had reported stockholders’ equity of less than $6 million as of June 30, 2019 and had net losses in its five most recent fiscal years. That being said, analyst Vernon Bernardino argues that the public offering is a move in the right direction. As a result, he reiterated his Buy rating and $5 price target. The H.C. Wainwright analyst believes shares could surge 71% in the next twelve months. NSPR boasts a ‘Moderate Buy’ analyst consensus and a $5 average price target, implying 71% upside potential. Zymeworks Inc. (ZYME)This biotech company develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. With shares up over 1% on August 23, some analysts believe now is the time to buy.Investors were impressed when ZYME posted strong Q2 earnings results on August 2. While EPS fell short of the consensus estimate by one cent, it was able to pull off a revenue beat.These results were boosted by a $7.5 million milestone payment from its partner Celgene (CELG) on July 16. The payment was triggered when CELG announced that it selected a lead oncology candidate and exercised its option for commercialization rights under their 2014 Azymetric agreement.After the news of the milestone payment broke, Deutsche Bank analyst Kostantinos Aprilakis told investors that the stock price represents a buying opportunity. This played into the analyst’s decision to initiate coverage with a Buy and set a $34 price target. He thinks shares could gain 36% in the next twelve months.In general, the Street takes a slightly more cautious stance on ZYME. It has a ‘Moderate Buy’ analyst consensus and a $29 average price target, suggesting 14% upside potential. Find analysts’ favorite stocks with the Top Analysts’ Stocks tool
InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that it has received a letter from the NYSE American on August 7, 2019, indicating that InspireMD does not meet a certain NYSE American LLC (the “NYSE American”) continued listing standard as set forth in Part 10, Section 1003(a)(iii) of the Company Guide of the NYSE American, due to the fact the Company had reported stockholders’ equity of less than $6 million as of June 30, 2019, and had net losses in its five most recent fiscal years ended December 31, 2018. The Exchange's notice has no immediate effect on the listing of the Company's common stock on the Exchange.
U.S. Investigational Device Exemption (IDE) application submitted to FDA Company to host investor conference call today, August 6, at 8:00am ET TEL AVIV, Israel, Aug. 06,.
TEL AVIV, Israel, July 30, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the.
InspireMD (NSPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On-Track to Submit U.S. IDE expected in Mid-2019 Company to Host Investor Conference Call at 8:00am ET TEL AVIV, Israel, May 14, 2019 -- InspireMD, Inc. (NYSE American:.
TEL AVIV, Israel, May 07, 2019 -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the.